CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression
N Bonnefoy, J Bastid, G Alberici, A Bensussan… - …, 2015 - Taylor & Francis
N Bonnefoy, J Bastid, G Alberici, A Bensussan, JF Eliaou
Oncoimmunology, 2015•Taylor & FrancisWe report that CD39–expressing-melanoma cells inhibited both T-cell proliferation and the
generation of cytotoxic effectors in an adenosine-dependent manner, and that treatment with
a CD39-blocking antibody alleviated tumor-mediated immunosuppression. Thus, blocking
CD39 ectonucleotidase may represent a novel immunotherapeutic strategy to restore
antitumor immunity.
generation of cytotoxic effectors in an adenosine-dependent manner, and that treatment with
a CD39-blocking antibody alleviated tumor-mediated immunosuppression. Thus, blocking
CD39 ectonucleotidase may represent a novel immunotherapeutic strategy to restore
antitumor immunity.
We report that CD39–expressing-melanoma cells inhibited both T-cell proliferation and the generation of cytotoxic effectors in an adenosine-dependent manner, and that treatment with a CD39-blocking antibody alleviated tumor-mediated immunosuppression. Thus, blocking CD39 ectonucleotidase may represent a novel immunotherapeutic strategy to restore antitumor immunity.
Taylor & Francis Online